CGS-15943

CGS-15943

Clinical data
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name 9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine
CAS Number	104615-18-1 Y
PubChem CID	2690
IUPHAR/BPS	384
ChemSpider	2589 Y
UNII	Y5A5D5E2AQ
ChEBI	CHEBI:131351 N
ChEMBL	ChEMBL16687 Y
CompTox Dashboard (EPA)	DTXSID80146617
Chemical and physical data
Formula	C13H8ClN5O
Molar mass	285.69 g·mol−1
3D model (JSmol)	Interactive image
SMILES ClC1=CC=C2N=C(N)N3N=C(C4=CC=CO4)N=C3C2=C1
InChI InChI=1S/C13H8ClN5O/c14-7-3-4-9-8(6-7)12-17-11(10-2-1-5-20-10)18-19(12)13(15)16-9/h1-6H,(H2,15,16) Y Key:MSJODEOZODDVGW-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

CGS-15943 is a drug which acts as a potent and reasonably selective antagonist for the adenosine receptors A₁ and A_2A, having a K_i of 3.3nM at A_2A and 21nM at A₁. It was one of the first adenosine receptor antagonists discovered that is not a xanthine derivative, instead being a triazoloquinazoline. Consequently, CGS-15943 has the advantage over most xanthine derivatives that it is not a phosphodiesterase inhibitor, and so has more a specific pharmacological effects profile. It produces similar effects to caffeine in animal studies, though with higher potency.

See also

• ATL-444
• SCH-58261